Plant-Based Diet for Coronary Artery Disease

This study is looking at how a specific plant-based diet affects people with coronary artery disease (CAD), a condition where blood vessels supplying the heart become narrowed. The study will involve 30 participants who will follow a defined plant-based diet for 42 days. Researchers will measure changes in your blood vessel function (endothelial function) at the beginning and after 4 weeks to see if the diet helps. You may be able to join if you are between 18 and 75 years old, have CAD, and are a new patient at the clinic. You cannot participate if you currently use tobacco, drink excessive alcohol, have cancer, an active infection, severe kidney disease (eGFR < 30), are pregnant or breastfeeding, or have been hospitalized in the last 6 months.

Study design
This is an interventional study planning to enroll 30 participants. It will compare a plant-based diet with standard medical care.
What's involved
You will follow a defined plant-based diet for 42 days. All food will be provided to you.
Compensation
Not stated in the trial record.
Follow-up
Your blood vessel function will be measured at enrollment and again at week 4.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06994624

Clinical and Biochemical Effects of a Defined Plant-Based Diet on Heart Disease

Recruiting
NAAges 18–75InterventionalTreatment
Georgia State University
~30 participants
Updated 2025-05-29 on ClinicalTrials.gov
What's tested:Nutritional intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improved endothelial function via reactive hyperemia index (RHI)
Measured over enrollment and at week 4
Coronary Artery Disease
1 sites across 1 states
Texas1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis with coronary artery disease (based on current EKG or prior diagnosis)
New patient

Exclusion

Current tobacco use
\>2 glasses of wine for woman, \>1 glass for men
Current cancer diagnosis
An ongoing clinically defined infection
eGFR \< 30
Pregnancy
Lactation
Prior hospitalization within past 6 months
Unstable angina
Heart catheterization within past 6 months
Cardiac perfusion study past 6 months
Have not been on any form of a plant-based diet previously
  • Improved endothelial function via reactive hyperemia index (RHI)enrollment and at week 4

    Peripheral microvascular function will be measured by PAT plethysmographic device (EndoPAT, Itamar®). The device consists of a finger probe with a transducer to assess digital volume changes accompanying pulse-waves. An inflatable cuff is placed on one arm (test arm), while amplitudes are recorded from the test arm and the contralateral control arm. Reactive hyperemia index (RHI) is obtained by the following: 5 minutes of baseline amplitude signal detection, 5 minutes of arterial occlusion by suprasystolic cuff inflation, and then 6 min of post-occlusion amplitude signal detection. RHI is a unit-less measure calculated as a ratio of hyperemic to baseline flow signal. It takes into account the baseline signal and adjusts it to the changes in the contralateral arm